de Boer, Carl G. http://orcid.org/0000-0001-8935-5921
Vaishnav, Eeshit Dhaval http://orcid.org/0000-0003-3720-8051
Sadeh, Ronen http://orcid.org/0000-0003-1920-3898
Abeyta, Esteban Luis http://orcid.org/0000-0001-5574-4822
Friedman, Nir http://orcid.org/0000-0002-9678-3550
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (K99-HG009920-01, CEGS)
Massachusetts Institute of Technology (Presidential Fellowship)
Israel Science Foundation (ICORE)
Howard Hughes Medical Institute
Article History
Received: 24 January 2019
Accepted: 16 October 2019
First Online: 2 December 2019
Change Date: 13 August 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-020-0665-2
Competing interests
: A.R. is an SAB member of Thermo Fisher Scientific, Neogene Therapeutics, Asimov, and Syros Pharmaceuticals, an equity holder of Immunitas, and a founder of and equity holder in Celsius Therapeutics. All other authors declare no competing interests.